BGM Group Ltd. (BGM)
D
Pipeline Grade
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-01-18 | Phase3 Readout | — |
| 2027-02-15 | Phase3 Readout | — |
Active Clinical Trials (13)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT02194738 | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by ... | OTHER | Active Not Recruiting | 8,300 |
| NCT04871542 | Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors | OTHER | Recruiting | 2,062 |
| NCT04242095 | Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects | OTHER | Recruiting | 240 |
| NCT06592794 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acu... | PHASE3 | Active Not Recruiting | 37,864 |
| NCT03793179 | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell... | PHASE3 | Active Not Recruiting | 600 |
| NCT05035212 | Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. | PHASE3 | Active Not Recruiting | 38,861 |
| NCT03155997 | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer | PHASE3 | Active Not Recruiting | 5,637 |
| NCT07064473 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabete... | PHASE3 | Recruiting | 11,800 |
| NCT05556512 | A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | PHASE3 | Active Not Recruiting | 15,374 |
| NCT06008756 | Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes | PHASE3 | Active Not Recruiting | 14,550 |
| NCT05567796 | A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight | PHASE3 | Active Not Recruiting | 3,400 |
| NCT04071457 | S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration | PHASE3 | Active Not Recruiting | 1,100 |
| NCT04266249 | CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | PHASE2 | Active Not Recruiting | 2,175 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.